Gujarat Themis Biosyn Limited (GUJTHEM)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 21 July 2026

₹364.55 ↑ 0.63% (1Y)

🎯 Key Takeaways

Gujarat Themis Biosyn Limited is in a consolidation and capital structure refinement phase, with promoter-led share transfers and regulatory compliance actions taking center stage. The company shows no active operational expansion or product commercialization signals in recent filings, suggesting a mature but non-growth-oriented phase.
⚠️ High valuation (P/E of 84.4) with no earnings growth trajectory visible in financial trends, making the stock vulnerable to earnings misses.

Market Cap

₹4,035

P/E Ratio

84.4

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About GUJTHEM 📊 Interactive Charts

📖 The Story

Gujarat Themis Biosyn Limited is in a consolidation and capital structure refinement phase, with promoter-led share transfers and regulatory compliance actions taking center stage. The company shows no active operational expansion or product commercialization signals in recent filings, suggesting a mature but non-growth-oriented phase. Financial performance remains subdued, with flat returns and high valuation multiples, indicating market skepticism about near-term catalysts.

📰 What's Happening

Promoter Sachin D. Patel has executed two inter-se share acquisitions in July 2026, purchasing 2.49 million shares from Themis Medicare Limited and proposing to acquire up to 525,000 shares from Pharmaceutical Business Group (India) Limited, collectively increasing his stake to 2.77%. These transactions are exempt from open offer under SEBI norms and are framed as promoter-level reorganizations rather than strategic investments. The company also cleared shareholder approval for a qualified institutional placement, signaling readiness to raise capital if needed. No new product launches, regulatory approvals, or capacity expansions were disclosed.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue, margins, or growth targets in the latest filings. The only forward-looking statement pertains to the timing of the share acquisition, which is scheduled between 21.07.2026 and 31.07.2026, with no commentary on post-acquisition strategic implications. The absence of operational or market expansion commentary indicates a hands-off approach to business development, focusing instead on capital structure management.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. High valuation (P/E of 84.4) with no earnings growth trajectory visible in financial trends, making the stock vulnerable to earnings misses. 2. Overreliance on promoter-level share transfers as a narrative driver, which lack strategic or operational significance. 3. Absence of management guidance or operational updates raises concerns about stagnation in core business momentum. 4. Regulatory scrutiny around insider trading disclosures adds compliance risk, even if transactions are technically compliant.

📋 Recent Filings

🧠 Analyst's Read

The company is currently in a quiet phase marked by procedural regulatory actions and minor capital adjustments rather than strategic momentum. Investors should watch for any operational updates, new product approvals, or expansion plans that could justify the current valuation. Until then, the stock remains driven by technical and promoter-level events rather than fundamental progress.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on GUJTHEM

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.

📡 Get AI alerts when GUJTHEM files new disclosures

Track GUJTHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GUJTHEM — Free

Free account · 2 AI queries/day